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Abstract 
Review on PTPN9, with data on DNA, on the protein 
encoded, and where the gene is implicated. 
Keywords: PTPN9; Endocytosis 
Identity 
Other names: PTPase-MEG2, PTPMEG2, MEG2 
HGNC (Hugo): PTPN9 
Location: 15q24.2 
DNA/RNA 
PTPN9 was originally cloned by screening libraries 
of the MEG-01 megakaryocyte leukemia cell line 
and of human umbilical vein endothelial cells (Gu 
1992). 
Description 
The PTPN9 gene was mapped to chromosome 
15q24.2 based on an alignment of the PTPN9 
sequence (GenBank BC010863) with the genomic 
sequence (GRCh37). 
Transcription 
MEG2 mRNA detected in 12 cell lines gave an 
indication that the protein tyrosine phosphatase  
(PTP) is widely expressed.  
A 4-kb RNA as analysed by Northern blot analysis 
was found in a variety of cell lines, indicating 
widespread expression of the gene (Gu 1992). 
Protein 
PTPN9 has a conserved PTP catalytic domain, and 
an NH2-terminal lipid-binding domain homologous 
to Sec14p, a yeast protein with phosphatidylinositol 
transferase activity, which is unique among PTPs 
(Gu 1992).  
The N-terminal 254 amino acids are about 28% 
identical to cellular retinaldehyde binding protein-1 
(RLBP1; 180090) and 24% identical to the yeast 
protein SEC14p.  
The former is a carrier protein for 11-cis-
retinaldehyde or 11-cis-retinol found in the retina 
and pineal gland, and the latter is a 
phosphatidylinositol transfer protein required for 
protein secretion from the Golgi apparatus.  
The PTPN9 cDNA encodes a 593-amino acid 
protein that has no apparent signal or transmembrane 
domains but does include a C-terminal region with a 
catalytic domain that shows 30-40% identity with 
other PTPs (http://www.omim.org/entry/600768). 
Figure 1.  Schematic diagram of recombinant PTPN9 protein (Adapted from Zhao et al. 2003).The open and solid bars indicate 
SEC14 lipid-binding domain and PTP catalytic domain, respectively. 
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Description 
PTPN9 is a 68-kDa, class I, cysteine-based, non-
receptor PTP is widely expressed in many cell types 
including the brain and leukocytes (Gu 1992, Saito 
2007). In these cells, most of the PTPN9 is located 
on the cytoplasmic face of secretory vesicles 
(Gjörloff-Wingren 2000, Wang 2002, Kruger 2002 
and Huynh 2004). On the cytoplasmic face of the 
enclosing membrane of secretory vesicles, PTPN9 
regulates vesicle size by promoting homotypic 
vesicle fusion through dephosphorylating NSF (N-
ethylmaleimide-sensitive factor), a key regulator of 
vesicle fusion (Saito 2007). PTPN9 structural 
uniqueness among mammalian PTPs lies in the fact 
that it contains a domain in its N terminus with 
homology to yeast Sec14p, a phosphatidylinositol-
binding protein (Sha 1998). This Sec14p homology 
(SEC14) domain of PTPN9 (Fig 1) is known to bind 
phosphoinositides (Kruger 2002, Huynh 2003, 
Krugmann 2002), a process that leads into enzymatic 
activation of the phosphatase domain (Kruger 2002, 
Huynh 2003). Using a series of deletion mutants, 
Saito et al identified the N-terminal SEC14 domain 
of PTPN9, residues 1-261, as the region containing 
the secretory vesicle targeting signal (Saito 2007). 
The SEC14 domain, alone or attached to a 
heterologous protein, was localized to intracellular 
vesicle membranes. In addition, two proteins, 
mannose 6-phosphate receptor-interacting protein 
PLIN3 (TIP47) and ARFIP2 Arfaptin2 altered 
PTPN9 localization when overexpressed, and 
elimination of TIP47 resulted in loss of PTPN9 
function. It has been shown that the truncated form 
of the N-terminal SEC14 domain of PTPN9 has a 
significantly higher activity than the full-length 
enzyme (Qi 2002, Kruger 2002). By using lipid-
membrane overlay and liposome binding assays, a 
specific binding of PTPN9 to phosphatidylserine 
was demonstrated (Zhao 2003). The binding was 
found to be mediated by the SEC14 domain. In intact 
cells, the SEC14 domain was found to play a 
prominent role in the localization of PTPN9 to the 
perinuclear region. Moreover, PTPN9 may play an 
important role through specific binding of 
phosphatidylserine, in regulating the signaling 
processes associated with phagocytosis of apoptotic 
cells (Zhao 2003). 
Expression 
The enzyme is expressed in many cell types (Gu 
1992, Saito 2007), including at low levels in Jurkat 
T cells (Gjörloff-Wingren 2000), mast cells and 
lymphocytes (Wang 2002, Wang 2005). 
Localisation 
Reports have shown PTPN9 residence on internal 
membranes, including secretory vesicles and 
granules in neutrophils and lymphocytes where it  
regulates secretory vesicle size and fusion (Gjörloff-
Wingren 2000, Wang 2002, Huynh 2003, Wang 
2005). It is possible that once engulfed by 
phagocytes, a high level of phosphatidylserine in the 
outer membrane of apoptotic cells may alter the 
distribution of PTPN9 in phagocytes (Zhao 2003). It 
has been suggested that the physiological function of 
PTPN9 may be to regulate formation of secretory 
vesicles of a defined and cell type-specific size 
(Wang 2002). PTPN9 expression is higher in mast 
cells (granule size 400-600 nm) than in lymphocytes 
(granule size 200-300 nm) (Wang 2002). 
Function 
It was proposed that PTPN9 promotes homotypic 
fusion of immature secretory vesicles, which is a 
major step in the formation of these vesicles from 
post-Golgi transport vesicles containing cargo 
destined for secretion (Wang 2002, Huynh 2004, 
Huynh 2003, Wang 2005, Mustelin 2004). 
Additionally, PTPN9 may represent a novel 
connection between dephosphorylation of tyrosine 
and the regulation of secretory vesicles in 
hematopoietic cells (Wang 2002). Moreover, the 
possibility of PTPN9 expression in controlling the 
extent of the secretory apparatus of hematopoietic 
cells was proposed. Huyhn et al showed that PTPN9 
regulates homotypic fusion of immature secretory 
vesicles by dephosphorylating the key regulator of 
vesicle fusion, N-ethylmaleimide-sensitive factor 
(NSF) (Huyhn 2004). PTPN9 can also regulate 
embryonic development (Wang 2005) and 
expansion of erythroid cells (Xu 2003). Studies have 
further demonstrated that PTPN9 controls insulin 
production, beta cell growth or insulin signaling by 
reducing insulin receptor (INSR) dephosphorylation 
in type II diabetes (Cho 2006, Chen 2010). Other 
studies have shown that PTPN9 promotes 
dephosphorylation of epidermal growth factor 
receptor (EGFR) and the receptor tyrosine protein 
kinase ERBB2, thereby impairing the activation of 
signal transducer and activator of transcription 3 
(STAT3) (Yuan 2010) and STAT5 (Yuan 2010, 
Furth 2011) in breast cancer cells. From their 
observations, it was suggested that PTPN9-mediated 
modulation of secretory vesicle genesis and function 
plays an essential role in neural tube, vascular, and 
bone development as well as activation may 
participate in the transfer of hydrophobic ligands or 
may be involved in Golgi-related functions (Gu 
1992). PTPN9 appears to regulate a balance by 
promoting fusion (anterograde transport) and 
reducing condensation (retrograde transport), thus 
increasing the size of secretory vesicles (Saito 2007). 
In addition, it was recently shown that the transport 
of neurotrophin receptor TRKA (NTRK1) to the cell 
surface requires PTPN9 activity (Zhang 2016). Trk 
A is a novel substrate of PTPN9 and is 
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dephosphorylated at both the kinase activation 
domain (Tyr674/675) and the signaling effector 
binding site (Tyr490). The studies were performed in 




ErbB family of the receptor protein-tyrosine kinase 
plays an important role in the progression of human 
cancers including breast cancer. Among the 43 
human protein-tyrosine phosphatases analysed, 
Yuan 2010 discovered the knockdown of PTPN9 to 
significantly increase ERBB2 tyrosine 
phosphorylation in the SKBR3 breast cancer cell 
line. Additionally, knockdown of PTPN9 expression 
enhances tyrosine phosphorylation of the 
ErbB1/EGFR in the MDA-MB-231 breast cancer 
cell line. Their data suggested PTPN9 to be a 
negative regulator of breast cancer cells through 
targeting ErbB2 and EGFR and inhibiting STAT 
activation (Yuan 2010). 
Hepatocellular carcinoma 
PTPN9 expression was down-regulated in human 
hepatocellular carcinoma (HCC) tumor tissues, 
associate with worsened overall survival in HCC 
patients (Hu 2016). Depletion ofPTPN9 inhibits the 
apoptosis and promotes the proliferation of HCC 
cells. 
Diabetes 
PTPN9 have been identified as a modulator of 
insulin-dependent FOXO1 subcellular localization 
(Cho 2006). Ectopic expression of PTPN9 in cells to 
suppress insulin-induced phosphorylation of the 
insulin receptor, while RNAi-mediated reduction of 
PTPN9 transcript levels enhanced insulin action. 
Their findings implicated PTPN9 as a mediator of 
blood glucose homeostasis through antagonism of 
insulin signaling, and proposed modulation of 
PTPN9 activity to be an adequate strategy in type 2 
diabetes treatment. Indeed, treatment with PTPN9 
inhibitors can lead to enhanced insulin action both in 
vitro and in vivo (Zhang 2012). 
Hematopoiesis 
Xu et al identified PTPN9 to be contained in 
erythroid colony-forming cells (ECFCs) from 
polycythemia vera (PV), a human clonal 
myeloproliferative disorder (Xu 2003). Increased 
activity of PTPN9 in PV cells to be attributed to its 
elevated distribution in the membrane fraction. 
Additionally, the findings showed that PTPN9 plays 
a major role in the development of erythroid cells. 
Immunodeficiency 
PTPN9-/- mice were reported to be immunodeficient 
as they displayed severe developmental 
malformations, such as defective skull formation and 
intracranial bleeding (Wang 2005). The mice 
remained small and the majority of them died before 
birth or within the first neonatal days. Furthermore, 
they detected defective platelet activation and very 
little interleukin-2 secretion in these mice. They 
attributed all these abnormalities to defective PTPN9 
secretion. 
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